All Prostascint Scan messages
Has anybody out there had any experience with having a ProstaScint scan done. My urologist wants me to have one since my PSA has begun very slightly to rise after 12 years. (from
The Adventure That Is Prostate Cancer
Michael Manyak, formerly of George Washington University Hospital and now with Cytogen (Prostascint Scans). Dr. Manyak was that invaluable, objective physician expert. In addition to recommending several physicians to see - he laid out ...
medicina nucleare
Il ProstaScint? ha una cinetica di eliminazione monoesponenziale, con una emivita di 67±11. ore. Il 72% della dose somministrata è escreto per via urinaria nelle prime 72 ore. L?irradiazione. dell?organismo intero è di 2.7 cGy. ...
Prostate Cancer: Management of Localized Disease
Bone scan; Chest radiography; CT scanning of the abdomen and pelvis; Potentially, transrectal ultrasound?guided rebiopsy of the prostate or prostatic fossa in patients treated with radical prostatectomy; ProstaScint scan (Cytogen; ...
data presented at snm meeting demonstrate new potential for ...
cytogen corporation (nasdaq: cyto) today announced the presentation of data from a series of studies with prostascint(r) (capromab pendetide), the first and only commercial monoclonal antibody-based agent that targets prostate-specific ...
Career Spotlight: Nuclear Pharmacy
There are a only a handful of agents available now: In-111 Capromab Pendetide (ProstaScint®) to image prostate cancer, and In-111/Y-90 Ibritumomab Tiuxetan (ZevalinTM) or I-131 Tositumomab (Bexxar®); however many more are in production. ...
seven-year survival data demonstrate use of cytogen's prostascint ...
link: seven-year survival data demonstrate use of cytogen's prostascint(r) independently predicts recurrence of prostate cancer. cytogen corporation today reported the publication of a seven-year survival study that suggests ...
fda approvals - new clinical data for prostascint(r) and quadramet ...
new clinical data for prostascint(r) and quadramet(r) in prostate cancer presented at the 2007 prostate cancer symposium (rednova) cytogen corporation (nasdaq: cyto) today report. st. jude medical receives fda clearance for venture ...
prostascint
only used in newly-diagnosed patients, or those post-prostatectomy with rising psa? printed out the pi, but can't find anything on usage after radiation. thanks in advance for any info.
